A Study of LY3981314 in Healthy Participants
Active, not recruiting · Phase 1 · NCT07005284
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $1.5M
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 76
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3981314 (drug), Placebo (drug)
- Dates
- Started 2025-06-09; completion 2027-02
- Results posted
- Not yet
The main purpose of this study is to investigate the safety of LY3981314 when administered subcutaneously (SC) (under the skin), and how it's processed in the body. The study will last approximately 25 weeks, excluding a screening period with an optional extension to approximately 49 weeks for qualifying participants.
From ClinicalTrials.gov, last updated 2026-05-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.5M in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Anaheim Clinical Trials LLC $1.5M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.